Revance Therapeutics Inc (RVNC)

[biotech_researcher]

RVNC/MYL Botox generic- I’ve got some mixed feelings on this. First, with all the potential indications that are in front of RT002, why tie up any of your limited resources developing a compound that you will ultimately be competing against? Plus, this product will no doubt cause price erosion to RT002 when the generic is introduced. Also, the $25 million upfront is pretty skimpy for such a disruptive product in the Botox space. Should have been $100 million. The good news is this product is 5-6 years from approval I assume. MYL was no doubt going to enter this space, but, strategically, not having Revance enter the picture could have added 12-24 months to Mylan’s development schedule, possibly. This could further solidify RT002 entrenchment.